On Feb. 1, Novartis Pharmaceuticals Canada Inc. announced that the Nova Scotia government is funding Pluvicto injections for ...
Diverse biomarkers, including PSA, BRCA mutations, PSMA, and AR-V7, guide treatment decisions in advanced prostate cancer management. Emerging biomarkers like ctDNA and PTEN loss offer predictive and ...
In a video interview, William K. Oh, MD, director of precision medicine at Yale Cancer Center and Smilow Cancer Hospital discusses the latest breakthroughs in advanced prostate cancer treatment.
The incidence of advanced prostate cancer in California rose markedly in the decade since doctors stopped routinely screening all men for the disease, according to a new study. Following a change ...
For mesothelioma cancer patients, the life expectancy is roughly 4-18 months after diagnosis, depending on if the patient pursues treatment. Patients diagnosed early have a general life expectancy of ...
A new UCSF study shows a significant increase in advanced prostate cancer cases in California, growing faster than the national average. This rise spans across all age groups, ethnicities ...
6. ADT can’t cure prostate cancer, but it can help you live longer. “ADT is a life-prolonging treatment,” says Siddiqui, “but it’s not curative.” The treatment can temporarily starve ...
By Joseph Goldstein New York City officials, intent on increasing residents’ life expectancy after ... are more likely to have breast cancer diagnosed at an advanced stage and to die from ...
The incidence of late grade 2 or greater GU toxicity at 5 years was 12.5% among those who did experience acute toxicity vs 7.5% among those who did not. “MPS2 could potentially improve the health of ...